Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)
Status:
Withdrawn
Trial end date:
2021-06-29
Target enrollment:
Participant gender:
Summary
This is a phase I study designed to assess the maximum tolerated dose (MTD) of pyrimethamine
and provide the recommended Phase 2 dose (RP2D) for the treatment of intermediate/high-risk
MDS that is refractory to or relapsed after treatment with azanucleosides.
Phase:
Phase 1
Details
Lead Sponsor:
Montefiore Medical Center University of Kansas Medical Center
Collaborators:
Albert Einstein College of Medicine Montefiore Medical Center